Following the Trump administration’s move to reschedule cannabis, White House Office of National Drug Control Policy (ONDCP) Director Sara Carter Bailey has clarified that cannabis remains “still illegal” under federal law. Director Bailey stated that the executive-level Schedule III classification primarily “allows for doctors and research and for medicine, for medicinal purposes,” as reported by Marijuana Moment.
This clarification underscores the ongoing federal-state dichotomy concerning cannabis policy, even as the landscape of medical cannabis rescheduling continues to evolve, building on earlier coverage by Hemp Gazette.
Regulatory Implications of Cannabis Rescheduling
The reclassification of cannabis to Schedule III of the Controlled Substances Act, while a significant administrative change, does not equate to full federal legalization. Director Bailey’s statement highlights that the primary intent is to facilitate medical research and prescription pathways, rather than to decriminalize or legalize the substance for broader use.
In response to the federal shift, the Oklahoma Bureau of Narcotics and Dangerous Drugs Control has issued guidance to state medical cannabis businesses. The guidance mandates that these businesses must register with the federal DEA to avoid potential sanctions, which could include the revocation of their state registrations. This requirement illustrates how federal administrative changes can trigger new compliance obligations at the state level for licensed operators.
Separately, a Pennsylvania senator has indicated that a bill to establish a new board for regulating medical cannabis and hemp in the state is “laying the foundation” for potential recreational marijuana legalization. The senator noted that the federal cannabis rescheduling move has influenced some more conservative members, suggesting a shifting political climate.
Industry and Market Response
The implications of federal cannabis rescheduling are also being assessed by state regulators. California regulators are currently conducting a survey to understand how the federal reclassification will impact the state’s regulated cannabis market, indicating a proactive approach to adapting to federal changes.
In corporate news, Cresco Labs Inc. reported quarterly net revenue of $151.3 million, alongside a net loss of $17 million, according to Marijuana Moment. This financial update provides insight into the performance of publicly traded cannabis companies within the current market environment. Furthermore, litigation accusing Cresco, Verano, and Cannabist of mislabeling marijuana products in Illinois has been dismissed, resolving a legal challenge for these operators.
Medical Cannabis Access and Research
A federally funded study published by the American Medical Association found that older adults are increasingly utilizing cannabis for symptom management. Many are motivated to try cannabis as an alternative to traditional pharmaceuticals due to concerns about adverse effects. The study noted that as cannabis legalization becomes more widespread, older adults are turning to it to manage symptoms associated with aging, including pain, sleep disturbances, and mental health concerns.
Other states have also seen regulatory activity impacting medical cannabis access and business operations:
- The Kentucky Finance and Administration Cabinet’s Office of the Inspector General released a report concluding that the state’s medical cannabis business licensing process was “fair and transparent.”
- Illinois regulators published guidance detailing child-resistant cannabis product packaging rules, enhancing consumer safety standards.
- Texas regulators issued a correction to previously announced medical cannabis business licensing scores and awards.
- Arkansas regulators renewed nearly all of the state’s medical cannabis business licenses, with a few delayed due to paperwork issues.
- Massachusetts regulators are scheduled to host a cannabis industry career fair on May 20, indicating ongoing sector growth and employment opportunities.
These state-level developments illustrate the varied regulatory and market responses to the evolving cannabis landscape, even as federal policy on cannabis rescheduling continues to be clarified.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
